These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 15006010

  • 1. Lipid-lowering therapy: strategies for improving compliance.
    Riesen WF, Darioli R, Noll G.
    Curr Med Res Opin; 2004; 20(2):165-73. PubMed ID: 15006010
    [Abstract] [Full Text] [Related]

  • 2. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program.
    J Am Coll Cardiol; 2004 Aug 04; 44(3):720-32. PubMed ID: 15358046
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov 04; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 5. Economic evaluation of a compliance-enhancing intervention in patients with hypercholesterolemia: design and baseline results of the Open Label Primary Care Study: Rosuvastatin Based Compliance Initiatives To Achievements of LDL Goals (ORBITAL) study.
    Willich SN, Müller-Nordhorn J, Sonntag F, Völler H, Meyer-Sabellek W, Wegscheider K, Windler E, Katus H.
    Am Heart J; 2004 Dec 04; 148(6):1060-7. PubMed ID: 15632894
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Achieving lipid goals in Europe: how large is the treatment gap?
    Schwandt P, Brady AJ.
    Expert Rev Cardiovasc Ther; 2004 May 04; 2(3):431-49. PubMed ID: 15151488
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial.
    Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, Braunwald E.
    Am Heart J; 2005 Mar 04; 149(3):444-50. PubMed ID: 15864232
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 5-year evaluation of electronic medical record flag alerts for patients warranting secondary prevention of coronary heart disease.
    Whitley HP, Fermo JD, Chumney EC.
    Pharmacotherapy; 2006 May 04; 26(5):682-8. PubMed ID: 16637797
    [Abstract] [Full Text] [Related]

  • 17. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
    Sever PS.
    Am J Med; 2005 Dec 04; 118 Suppl 12A():3-9. PubMed ID: 16356801
    [Abstract] [Full Text] [Related]

  • 18. [Cholesterol: blood levels or total risk as a guide to preventive treatment?].
    Mathes P.
    Z Kardiol; 2004 Dec 04; 93 Suppl 2():II16-20. PubMed ID: 15021991
    [Abstract] [Full Text] [Related]

  • 19. New evidence supporting aggressive lipid lowering.
    Stein EA.
    Postgrad Med; 2003 Apr 04; 113(4 Suppl):31-40. PubMed ID: 19667621
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.